利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤疗效观察

Effect of rituximab combined with CHOP chemotherapy on B cell non-hodgkin's lymphoma

目的观察利妥昔单抗联合CHOP化疗对B细胞非霍奇金淋巴瘤的治疗效果,并探讨利妥昔单抗治疗对患者免疫功能的影响。方法 62例初治CD20阳性的B细胞NHL患者,随机分为RCHOP组(29例)和CHOP组(33例),分别采用利妥昔单抗联合CHOP方案和单用CHOP方案化疗。结果 RCHOP组缓解率为55.2%,总有效率为82.8%,CHOP组缓解率为39.4%,总有效率为57.6%。RCHOP组患者化疗后大多数出现免疫球蛋白水平的明显下降,感染率为44.8%,CHOP组患者化疗后免疫球蛋白水平无明显下降,感染率仅为15.2%。结论利妥昔单抗联合CHOP方案的效果明显优于单用CHOP方案,但利妥昔单抗治疗可致机体淋巴细胞减少,影响免疫球蛋白的生成,增加患者机会性感染的可能。

Objective To observe the effect of rituximab combined with CHOP chemotherapy on B cell non-hodgldn＇s lymphoma, and discuss its influence to patient＇s immune function. Methods Sixty-two newly diagnosed patients with CD2o positive B cell NHL were randomly divided into two groups： RCHOP group （n=29, treated with ritux- imab combined with CHOP chemotherapy）, CHOP group （n=33, treated with CHOP regimen only）. Results The com- plete remission （CR） rate and total response rate in RCHOP group were 55. 2% and 82.8%, and the corresponding rates in CHOP group were 39.4% and 57.6%. The average immunoglobulin level of RCHOP group decreased signifi- cantly after chemotherapy, and the infection rate was 44.8%. The average immunoglobulin level of CHOP group showed no significant decrease after chemotherapy, and the infection rate was 15.2%. Conclusion Compared with CHOP chemotherapy, rituximab combined with CHOP chemotherapy showes higher therapeutic effects, but it could decrease the patient＇s lymphocytes, affect the production of immunoglobulin, and increase patient＇s opportunistic infec- tions probability.